Emerging Trends in Biotech/Pharmaceutical Collaborations
نویسنده
چکیده
This decline can be attributed primarily to a more cautious regulatory climate caused by recent highprofile safety issues. 3 As a result of the heightened bar to obtain FDA approval, the life sciences sector has been plagued by a dearth of new product flow. All players in the industry—even large pharmaceutical companies—have been affected. Notably, only Novartis and GlaxoSmithKline (GSK) released more than one drug in 2007. 4
منابع مشابه
Putting the “Co” in Development and Promotion
While collaborations between emerging biotechnology companies and pharma/biopharma companies are not new, these deals dramatically have increased in sheer number and deal value. Perhaps the most important recent trend to note is a structural one—a trend away from the conventional royalty model toward 50/50 cost and profit sharing collaborations. Last year, even small, emerging biotech companies...
متن کاملEssential Drugs Production in Brazil, Russia, India, China and South Africa (BRICS): Opportunities and Challenges
The objective of this work is to elucidate various essential drugs in the Brazil, Russia, India, China and South Africa (BRICS) countries. It discusses the opportunities and challenges of the existing biotech infrastructure and the production of drugs and vaccines in member states of the BRICS. This research is based on a systematic literature review between the years 2000 and 2014 of documents...
متن کامل11th International Congress on Targeted Anticancer Therapies
paris, france, 4–6 March 2013 The Targeted Anticancer Therapies (TAT) conference provides a forum for in-depth discussion of emerging targeted agents for the treatment of cancer. TAT conferences are characterized by focus on emerging innovative agents with a cancer-specific molecular target, gathering the world’s leading oncology Phase I investigators. They attract a mix of professionals with d...
متن کاملVirtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
Research and development (R&D) collaborations represent one approach chosen by the pharmaceutical industry to tackle current challenges posed by declining internal R&D success rates and fading of the blockbuster model. In recent years, a flexible concept to collaborate in R&D has emerged: virtual pharmaceutical companies (VPCs). These differ from other R&D companies, such as biotech start-ups, ...
متن کاملRacing to define pharmaceutical R&D external innovation models.
The pharmaceutical industry continues to face fundamental challenges because of issues with research and development (R&D) productivity and rising customer expectations. To lower R&D costs, move beyond me-too therapies, and create more transformative portfolios, pharmaceutical companies are actively capitalizing on external innovation through precompetitive collaboration with academia, cultivat...
متن کامل